Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Delighted to deliver a lecture at the ASCO26 Clinical Science Symposium Session on one of the most exciting frontiers in sarcoma therapeutics – American Society of Clinical Oncology (ASCO) Annual meeting 2026
‘To Boldly Deliver Where No Drug Has Gone Before: Antibody-Drug Conjugates in Sarcoma’
- ADCs have transformed the treatment landscape across breast, lung, gastric, & urothelial cancers.
- The question now, can we boldly deliver this precision-guided payload paradigm to sarcoma a family of >100+ rare + ultra-rare histologies long underserved by drug development?
- Join us for a deep dive into the science, the targets, the trials, and what’s next, with amazing speakers.
- Monday, June 1, 2026 | 8:00–9:30 AM CDTRoom S504,
- McCormick Place
- In-person only
Add to your agenda – see you all in Chicago.”
Other articles featuring Vivek Subbiah on OncoDaily.